NCT01878201

A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension

A Randomized, Double-blind, Valsartan 80 Mg-Referenced, Parallel Grouped, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 75 (actual)
• Sponsor: Boryung Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to Evaluate the Antihypertensive efficacy of Fimasartan 30 mg during 24 hours in Patients with Mild to Moderate Essential Hypertension

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	Fimasartan	Fimasartan 30 mg
DRUG	Valsartan	Valsartan 80 mg

Timeline

• Start date: 2013-05-01
• Primary completion: 2014-02-01
• Completion: 2014-02-01
• First posted: 2013-06-14
• Last updated: 2014-09-08

Locations

1 site across 1 country: South Korea